Page last updated: 2024-10-15

ci 972

Description

CI 972: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135418360
CHEMBL ID554876
MeSH IDM0191686

Synonyms (16)

Synonym
ci 972
115787-68-3
chembl554876 ,
4h-pyrrolo(3,2-d)pyrimidin-4-one, 2,6-diamino-1,5-dihydro-7-(3-thienylmethyl)-, monohydrochloride
DTXSID10151193
2,6-diamino-3,5-dihydro-7-(3-thienylmethyl)-4h-pyrrolo[3,2-d]pyrimidin-4-one monohydrochloride
2,6-diamino-7-[(thiophen-3-yl)methyl]-3h,4h,5h-pyrrolo[3,2-d]pyrimidin-4-one hydrochloride
SLNICZJKQXPOJA-UHFFFAOYSA-N ,
2,6-diamino-3,5-dihydro-7-(3-thienylmethyl)-4h-pyrrolo[3,2-d]pyrimidin-4-one, hydrochloride
ci 972 (anhydrous)
HY-118047
CS-0065089
2,6-diamino-7-(thiophen-3-ylmethyl)-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one;hydrochloride
2,6-diamino-7-(thiophen-3-ylmethyl)-3h-pyrrolo[3,2-d]pyrimidin-4(5h)-one hydrochloride
AKOS040741550
ci 972 anhydrous
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Purine nucleoside phosphorylaseHomo sapiens (human)IC50 (µMol)0.90000.00351.49875.0000AID164912
Purine nucleoside phosphorylaseHomo sapiens (human)Ki0.83000.00000.52897.0000AID164920
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
inosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
urate biosynthetic processPurine nucleoside phosphorylaseHomo sapiens (human)
positive regulation of T cell proliferationPurine nucleoside phosphorylaseHomo sapiens (human)
positive regulation of alpha-beta T cell differentiationPurine nucleoside phosphorylaseHomo sapiens (human)
allantoin metabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
nucleobase-containing compound metabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
inosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
deoxyinosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
deoxyadenosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
purine ribonucleoside salvagePurine nucleoside phosphorylaseHomo sapiens (human)
IMP catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
nicotinamide riboside catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
immune responsePurine nucleoside phosphorylaseHomo sapiens (human)
nucleotide biosynthetic processPurine nucleoside phosphorylaseHomo sapiens (human)
response to xenobiotic stimulusPurine nucleoside phosphorylaseHomo sapiens (human)
positive regulation of interleukin-2 productionPurine nucleoside phosphorylaseHomo sapiens (human)
purine-containing compound salvagePurine nucleoside phosphorylaseHomo sapiens (human)
dAMP catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
nucleoside bindingPurine nucleoside phosphorylaseHomo sapiens (human)
purine nucleobase bindingPurine nucleoside phosphorylaseHomo sapiens (human)
purine-nucleoside phosphorylase activityPurine nucleoside phosphorylaseHomo sapiens (human)
protein bindingPurine nucleoside phosphorylaseHomo sapiens (human)
phosphate ion bindingPurine nucleoside phosphorylaseHomo sapiens (human)
identical protein bindingPurine nucleoside phosphorylaseHomo sapiens (human)
guanosine phosphorylase activityPurine nucleoside phosphorylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
extracellular regionPurine nucleoside phosphorylaseHomo sapiens (human)
cytoplasmPurine nucleoside phosphorylaseHomo sapiens (human)
cytosolPurine nucleoside phosphorylaseHomo sapiens (human)
secretory granule lumenPurine nucleoside phosphorylaseHomo sapiens (human)
extracellular exosomePurine nucleoside phosphorylaseHomo sapiens (human)
ficolin-1-rich granule lumenPurine nucleoside phosphorylaseHomo sapiens (human)
cytoplasmPurine nucleoside phosphorylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID164934Compound was evaluated for the inhibitory activity against purine nucleoside phosphorylase (PNP) as a function of time of dialysis after 24 hours at 5 uM concentration1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-th
AID164932Compound was evaluated for the inhibitory activity against purine nucleoside phosphorylase (PNP) as a function of time of dialysis after 0 hours at 5 uM concentration1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-th
AID223844Compound was evaluated for the inhibitory activity against purine nucleoside phosphorylase (PNP) as a function of time of dialysis after 6 hours at 5 uM concentration1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-th
AID23553Solubility in water1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-th
AID164912Compound was tested for the inhibitory activity against purine nucleoside phosphorylase (PNP)1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-th
AID164920Ability to inhibit purine nucleoside phosphorylase (PNP)1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-th
AID105654Compound was tested for the cytotoxic activity against MOLT-4 lymphoblasts1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-th
AID16054Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-th
AID164935Compound was evaluated for the inhibitory activity against purine nucleoside phosphorylase (PNP) as a function of time of dialysis after 3 hours at 5 uM concentration1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-th
AID23441Partition coefficient in octanol/water system was determined at pH 7.4, as a measure of lipophilicity.1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-th
AID106500Compound was tested for the cytotoxic activity against MGL-8(B-cell) lymphoblasts1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-th
AID164933Compound was evaluated for the inhibitory activity against purine nucleoside phosphorylase (PNP) as a function of time of dialysis after 1 hours at 5 uM concentration1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-th
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (90.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]